Biscayne to Present Breakthrough Data at Breast Cancer Symposium 2014 on GHRH Target

Biscayne to Present Breakthrough Data at Breast Cancer Symposium 2014 on GHRH Target

GHRHBiopharmaceutical company Biscayne Pharmaceuticals Inc. announced that they will present data supporting the anti-cancer potential of their growth hormone-releasing hormone (GHRH) technology, which will be featured in a presentation at the American Society of Clinical Oncology's (ASCO) Breast Cancer Symposium 2014, taking place this week in San Francisco, California. To be introduced by Biscayne's Medical Director Norman Block MD, who is also the clinical director of the Endocrine Polypeptide and Cancer Institute at the Veterans Affairs Medical Center in Miami and the L. Austin Weeks Family Professor of Urologic Research at the University of Miami Miller School of Medicine, the lecture will focus on recent cancer research breakthroughs.

GHRH releases hormones responsible for the growth and tissue repair of brain cells. As a part of ongoing research, renowned scientist and Nobel winner Andrew V. Schally discovered that other cells throughout the body, including cancer cells, also have receptors for GHRH. Cancer cells not only hold GHRH receptors, but also produce GHRH hormones, enabling their own growth. Based on the discovery, which was licensed by Biscayne, the company is developing GHRH antagonists aimed to block the tumor growth, as well as the activity of the receptors on cancer cells.

"Extensive studies in preclinical models gave us conf

Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.